Stay updated on Trastuzumab Deruxtecan+Nivolumab in Breast & Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Deruxtecan+Nivolumab in Breast & Urothelial Cancer Clinical Trial page.

Latest updates to the Trastuzumab Deruxtecan+Nivolumab in Breast & Urothelial Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA minor site update adds Revision: v3.4.2 and removes the previous maintenance notice (Revision: v3.4.1) related to government funding.SummaryDifference0.3%

- Check21 days agoChange DetectedA government funding notice and site status message are now displayed, and the revision label updated from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check28 days agoChange DetectedAdded a 'Show glossary' option and updated wording for No FEAR Act data, capitalization of QC criteria labels, and revision notes (v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision metadata updated: added Revision: v3.3.4 and removed Revision: v3.3.3. No substantive changes to the study content (e.g., eligibility criteria, outcomes, or interventions) are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page’s Locations section was updated with additions and removals of study sites across multiple states and countries (e.g., CA, CT, FL, KY, NY, NC, OH, TN, UT, WA, and European locations).SummaryDifference1%

- Check92 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2 with no changes to the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Trastuzumab Deruxtecan+Nivolumab in Breast & Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Deruxtecan+Nivolumab in Breast & Urothelial Cancer Clinical Trial page.